How much revenue does Shandong Sinobioway Biomedicine make?

Shandong Sinobioway Biomedicine reported 274.81 million CNY in revenue for fiscal year 2025, down 23.7% from 360.41 million CNY in fiscal year 2024. In Q1 2026 revenue was 43.86 million CNY.

What companies are similar to Shandong Sinobioway Biomedicine?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ), Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ), Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ), Shanghai Fudan Forward S&T Co., Ltd (600624.SS).

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) Stock

About Shandong Sinobioway Biomedicine Co., Ltd.

Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Yi...

At a glance

Shandong Sinobioway Biomedicine reported revenue of 274.81 million CNY for fiscal year 2025, down 23.7% from fiscal year 2024, and net income of -116.28 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 43.86 million CNY, up 24.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.